CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells

Lung Cancer

Volumn 82, Issue 3, 2013, Pages 477-484

  Grabauskiene, Svetlana ^a   Bergeron, Edward J ^a   Chen, Guoan ^a   Chang, Andrew C ^a,b   Lin, Jules ^a,b   Thomas, Dafydd G ^a,b   Giordano, Thomas J ^a,b   Beer, David G ^a,b   Morgan, Meredith A ^a,b   Reddy, Rishindra M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Chemosensitivity; CHK1; Genomic complexity; Lung; NSCLC; Patient survival

Indexed keywords

CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 INHIBITOR; ENZYME INHIBITOR; MESSENGER RNA; MK 8776; PEMETREXED; PROTEIN P53; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; WESTERN BLOTTING;

CHECKPOINT KINASE 1; CHEMOSENSITIVITY; CHK1; GENOMIC COMPLEXITY; LOH; LOSS OF HETEROZYGOSITY; LUNG; NON-SMALL CELL LUNG CANCER; NSCLC; PATIENT SURVIVAL; PEMETREXED; PMX; RMA; ROBUST MULTI-ARRAY AVERAGE;

AGED; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN KINASES; PYRAZOLES; PYRIMIDINES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887607039     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.09.010     Document Type: Article

References (35)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J Clin 2010, 60:277-300.
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98. Eastern Cooperative Oncology Group.
3. Bryant C.M., Albertus D.L., Kim S., Chen G., Brambilla C., Guedj M., et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS ONE 2010, 5:e11712.
4. Hayes D.N., Monti S., Parmigiani G., Gilks C.B., Naoki K., Bhattacharjee A., et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006, 24:5079-5090.
5. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967. Spanish Lung Cancer Group.
6. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1770.
7. Zhou J., Chen Z., Malysa A., Li X., Oliveira P., Zhang Y., et al. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. PLoS ONE 2013, 8:e58091.
8. Carrassa L., Broggini M., Erba E., Damia G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing, or not, p53. Cell Cycle 2004, 3:1175-1179.
9. Sorensen C.S., Hansen L.T., Dziegielewski J., Syljuasen R.G., Lundin C., Bartek J., et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005, 7:195-201.
10. Dai Y., Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010, 16:376-383.
11. Morgan M.A., Parsels L.A., Zhao L., Parsels J.D., Davis M.A., Hassan M.C., et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010, 70:4972-4981.
12. Parsels L.A., Morgan M.A., Tanska D.M., Parsels J.D., Palmer B.D., Booth R.J., et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009, 8:45-54.
13. Mitchell J.B., Choudhuri R., Fabre K., Sowers A.L., Citrin D., Zabludoff S.D., et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010, 16:2076-2084.
14. Montano R., Chung I., Garner K.M., Parry D., Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther 2012, 11:427-438.
15. Chen Z., Xiao Z., Gu W.Z., Xue J., Bui M.H., Kovar P., et al. Selective Chk11 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 2006, 119:2784-2789.
16. Ma C.X., Janetka J.W., Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011, 17:88-96.
17. Koniaras K., Cuddihy A.R., Christopoulos H., Hogg A., O'Connell M.J. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 2001, 20:7453-7456.
18. Shedden K., Taylor J.M., Enkemann S.A., Tsao M.S., Yeatman T.J., Gerald W.L., et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008, 14:822-827.
19. Guzi T.J., Paruch K., Dwyer M.P., Labroli M., Shanahan F., Davis N., et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther 2011, 10:591-602.
20. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
21. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898.
22. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
23. Zhou B.B., Peyton M., He B., Liu C., Girard L., Caudler E., et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006, 10:39-50.
24. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
25. Nocito A., Kononen J., Kallioniemi O.P., Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001, 94:1-5.
26. Wang S., Saboorian M.H., Frenkel E., Hynan L., Gokaslan S.T., Ashfaq R. Laboratory assessment of the status of her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000, 53:374-381.
27. Lawrence T.S. Ouabain sensitizes tumor cells but not normal cells to radiation. Int Radiat Oncol Biol Phys 1998, 15:953-958.
28. Silvers A.L., Lin L., Bass A.J., Chen G., Wang Z., Lin J., et al. Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clin Cancer Res 2010, 16(7):2009-2021.
29. Parsels L.A., Qian Y., Tanska D.M., Gross M., Zhao L., Hassan M.C., et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res 2011, 17:3706-3715.
30. Bartucci M., Svensson S., Romania P., Dattilo R., Patrizii M., Signore M., et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ 2012, 19:768-777.
31. Hong J., Hu K., Yuan Y., Sang Y., Bu Q., Chen G., et al. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Invest 2012, 122:2165-2167.
32. Ma C.X., Cai S., Li S., Ryan C.E., Guo Z., Schaiff W.T., et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 2012, 122:1541-1552.
33. Cho S.H., Toouli C.D., Fujii G.H., Crain C., Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 2005, 4:131-139.
34. Bartek J., Bartkova J., Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007, 26:7773-7779.
35. Bartkova J., Hamerlik P., Stockhausen M.T., Ehrmann J., Hlobilkova A., Laursen H., et al. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 2010, 29:5095-5102.